Rett Syndrome Treatment: Trofinetide Faces EMA Re-examination

Acadia Pharmaceuticals will re-examine its application for European market authorisation of trofinetide, a treatment for Rett syndrome, following a rejection from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP). The decision follows a “negative trend vote” by the CHMP in February, according to reports.

The CHMP cited concerns regarding the magnitude of effect observed in clinical trials and the ability of the trials to fully capture the spectrum of core symptoms associated with Rett syndrome. Despite the setback, Acadia indicated it would address the committee’s feedback in a renewed application process.

Neuren Pharmaceuticals, Acadia’s US-listed partner in the development of trofinetide, voiced its support for the re-examination. “Trofinetide has been making a difference for patients for nearly three years in approved markets and the unmet medical need in Europe remains substantial and urgent,” said Neuren CEO Jon Pilcher. Trofinetide is currently approved for use in the United States, Canada, and Israel.

The CHMP’s decision comes after a period of scrutiny regarding the drug’s efficacy data. While approved in other regions, the EMA’s assessment suggests a higher threshold for demonstrating clinical benefit within the European market. The re-examination process will likely involve a detailed review of the clinical trial data and a response to the specific concerns raised by the CHMP.

Analysts have noted the regulatory challenges facing biotech firms, as highlighted by recent difficulties experienced by Neuren. The differing regulatory standards between regions underscore the complexities of bringing new treatments to market globally.